Compass Therapeutics, Inc. — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-0
Book Value Per Share
$1
Free Cash Flow Per Share
$-0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity
-41.3%
Return on Assets
-36.9%
Return on Invested Capital
-35.7%
Debt to Equity
—
Current Ratio
15.02
Quick Ratio
15.02
Asset Turnover
0.00
R&D / Revenue
4981.4%
SBC / Revenue
1007.1%
Capex / Revenue
5.2%
Working Capital
$196M
Net Current Asset Value
$187M
Invested Capital
$197M
OCF / Net Income
0.74
FCF / Net Income
0.74
Accruals Ratio (Sloan)
-7.9%
Net Debt
$-209M
Net Debt / EBITDA
2.88
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-1965.72
Tangible Common Equity
$197M
TCE / Total Assets
89.6%
NOPAT
$-58M
Cash ROIC
-30.5%
WC / Revenue
14573.8%
Capex / D&A
0.09
Reinvestment Rate
0.3%
Asset Growth vs Revenue Growth
156.4%
Book Value 5Y CAGR
37.6%
Stock Price (FY-end)
$5
Market Cap
$199M
P/S Ratio
234.39
P/B Ratio
1.59
P/TB Ratio
1.59
Enterprise Value
$73M
EV / Sales
85.30
FCF Yield
-22.5%
Shareholder Yield
-4.3%
R&D Yield
21.3%
Capex Yield
0.0%
Beta (5Y)
1.01
Cost of Equity
9.5%
Cost of Debt (after tax)
—
52W High
$6
52W Low
$1
Trailing Return 1Y
267.8%
F-Score (Piotroski)
3.00
Z-Score (Altman)
3.98
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.